We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Spina Bifida Surgery Recommended in Utero

By HospiMedica International staff writers
Posted on 05 Mar 2012
A new study suggests that for children with spina bifida (myelomeningocele), surgery conducted while the fetus is still in the uterus is more cost effective, due to the costs associated with caring for a child with significant deficits.

Researchers at Johns Hopkins University (JHU; Baltimore, MD, USA) built a decision model to evaluate the costs and effects to the health care system of in utero surgery, compared to surgery shortly after birth for children with spina bifida. More...
The researchers assumed that prenatal surgery was associated with improved neurological outcomes and changed the need for other surgical interventions in offspring, such as ventriculoperitoneal (VP) shunting, surgery for tethered spinal cord, and Chiari malformation. The researchers also accounted for adverse outcomes due to prenatal surgery and unintended risks for future pregnancies after prenatal surgery. The primary outcome was the incremental cost-effectiveness ratio (ICER).

The researchers found that the model predicted that every 100 fetal myelomeningocele repairs result in a cost savings of USD 3,135,557, and an improved quality of life (QALY), calculating the ICER to be USD 48,993 per QALY gained. The researchers further estimated that for every 100 prenatal repairs, QALYs are increased by 96 for the neonates with myelomeningocele, but maternal QALYs are reduced by 23, and future sibling QALYs are reduced by 9. In all, prenatal surgery was found to be cost saving in 55% of simulations, and cost-effective in 72%. The study was presented at the Society for Maternal-Fetal Medicine annual meeting, held during February 2012 in Dallas (TX, USA).

“Given the large costs associated with caring for a child with significant deficits, the improved outcomes with in utero surgery make it less costly over a lifetime than surgery after delivery,” said study coauthor Erika Werner, MD, of the JHU department of gynecology and obstetrics.

Spina bifida is a developmental congenital disorder caused by the incomplete closing of the embryonic neural tube; if the opening is large enough, this allows a portion of the spinal cord to protrude through the opening in the bones. Myelomeningocele is the most significant form of spina bifida, with the most common location of the malformations in the lumbar and sacral areas. Spina bifida can be surgically closed after birth, but this does not restore normal function to the affected part of the spinal cord. The incidence of spina bifida can be decreased by up to 70% when daily folic acid supplements are taken prior to conception.

Related Links:

Johns Hopkins University




Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.